First-line benmelstobart plus anlotinib versus sunitinib in advanced renal cell carcinoma (ETER100): a multicentre, randomised, open-label, phase 3 trialAiping Zhou, Xinan Sheng, Zengjun Wang et al.|The Lancet Oncology|2025Cited by 10
Education Level as a Predictor of Survival in Patients with Multiple MyelomaLimei Xu, Juan Li|Research Square|2020Cited by 4